Unaudited NAV for January 2023

Arix Bioscience PLC (ARIX)
Unaudited NAV for January 2023

06-Feb-2023 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


 

 

Arix Bioscience plc

 

Unaudited NAV for January 2023

 

LONDON, 6 February 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited Net Asset Value (“NAV”) of the Company for the date ended 31 January 2023 as follows:

 

Date

NAV Breakdown

Total NAV

 

NAV per share

Listed Portfolio

Unlisted Portfolio

Cash

Other Interests

31 January 2023

(unaudited)

£50.8m

£55.8m

£123.3m

£3.0m

£232.9m

£1.80

 

 

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 



ISIN: GB00BD045071
Category Code: MSCM
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 220795
EQS News ID: 1551783

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1551783&application_name=news&site_id=financialexpress
UK 100

Latest directors dealings